Lumosa Therapeutics , Ltd. Overview
Lumosa Therapeutics , Ltd. (6535.TWO) has a ROE of -29.89%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-29.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Lumosa Therapeutics , Ltd.'s return on equity stands at -29.89%. That is above the Healthcare sector average of -100.59%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Lumosa Therapeutics , Ltd. sits higher the Healthcare benchmark (-100.59%) with a ROE of -29.89%. That is roughly 70.3% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of -29.89% for Lumosa Therapeutics , Ltd. means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Lumosa Therapeutics , Ltd.'s ROE evolved across reporting periods, while the comparison chart places 6535.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Lumosa Therapeutics , Ltd.'s reading of -29.89% (sector avg -100.59%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
